Gorlin Companies

Gorlin Companies

Steve Gorlin established Gorlin Companies in 2006 after more than four decades creating and exiting biotechnology firms. The family office channels proceeds from those transactions into new healthcare ventures. Gorlin works with founders on management, operations, and capital raises. The firm invests in biotech and pharma at seed through Series C stages. It uses direct co-investments and SPVs alongside occasional fund commitments. Confirmed current holdings include CoRegen, C-Polar Technologies, Senvi, Oxia, and Intrepro. Realized positions encompass HYCOR Biomedical, Theragenics, CytRx, Medicis Pharmaceutical, EntreMed, Medivation, MiMedx, and Kabbage. Activity centers on North America with emphasis on companies that hold immediate international potential. Gorlin Companies maintains offices in Aspen and New York. Additional family assets include residential property in Destin and an art collection in Southampton. Steve Gorlin and Elena Ulansky serve as trustees of National Jewish Health. In the last 24 months no public operational announcements appeared in available records. The office maintains a hybrid model that combines principal-led company building with selective co-investments. This structure allows repeated use of the same operational playbook across successive healthcare platforms rather than relying on third-party fund selection.